Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE Trial

on behalf of J-TASTE investigators

Research output: Contribution to journalArticle

Abstract

Background: Previous studies suggest that the pathophysiology of heart failure with preserved ejection fraction (HFpEF) is characterized not only by high ventricular stiffness, but also by vascular stiffness. Azilsartan has higher vascular affinity compared with other angiotensin II receptor blockers (ARBs), which were proven to have no beneficial effects on clinical outcomes in patients with HFpEF in earlier clinical trials. We aimed to test the hypothesis that azilsartan may improve left ventricular diastolic function in HFpEF patients with hypertension in this trial. Methods: The Effects of Angiotensin Receptor Blockers on Diastolic Function in Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE trial is a multicenter, randomized, open-labeled, and assessor(s)-blinded, active controlled using candesartan, parallel-group clinical trial, to compare changes in left ventricular (LV) diastolic dysfunction between HFpEF patients with hypertension who have received candesartan or azilsartan for 48 weeks. The primary endpoint is the change in early diastolic wave height/early diastolic mitral annulus velocity (E/e’) assessed by echocardiography from the baseline to the end of the study (48 weeks). A total of 190 patients will be recruited into the study. Conclusions: The design of the J-TASTE trial will provide data on whether differences between the effects of the two tested drugs on LV diastolic function exist in HFpEF patients with hypertension and will improve understanding of the pathophysiological role of vascular stiffness on diastolic function.

Original languageEnglish
Pages (from-to)381-388
Number of pages8
JournalCardiovascular Drugs and Therapy
Volume32
Issue number4
DOIs
Publication statusPublished - 01-08-2018

Fingerprint

Angiotensin Receptor Antagonists
Multicenter Studies
Japan
Heart Failure
Vascular Stiffness
Hypertension
Left Ventricular Function
Clinical Trials
Left Ventricular Dysfunction
Blood Vessels
Echocardiography
azilsartan
candesartan
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

@article{ae16b997198249ff8fcd97324c4e98cb,
title = "Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE Trial",
abstract = "Background: Previous studies suggest that the pathophysiology of heart failure with preserved ejection fraction (HFpEF) is characterized not only by high ventricular stiffness, but also by vascular stiffness. Azilsartan has higher vascular affinity compared with other angiotensin II receptor blockers (ARBs), which were proven to have no beneficial effects on clinical outcomes in patients with HFpEF in earlier clinical trials. We aimed to test the hypothesis that azilsartan may improve left ventricular diastolic function in HFpEF patients with hypertension in this trial. Methods: The Effects of Angiotensin Receptor Blockers on Diastolic Function in Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE trial is a multicenter, randomized, open-labeled, and assessor(s)-blinded, active controlled using candesartan, parallel-group clinical trial, to compare changes in left ventricular (LV) diastolic dysfunction between HFpEF patients with hypertension who have received candesartan or azilsartan for 48 weeks. The primary endpoint is the change in early diastolic wave height/early diastolic mitral annulus velocity (E/e’) assessed by echocardiography from the baseline to the end of the study (48 weeks). A total of 190 patients will be recruited into the study. Conclusions: The design of the J-TASTE trial will provide data on whether differences between the effects of the two tested drugs on LV diastolic function exist in HFpEF patients with hypertension and will improve understanding of the pathophysiological role of vascular stiffness on diastolic function.",
author = "{on behalf of J-TASTE investigators} and Hiroyuki Takahama and Masanori Asakura and Yukio Abe and Masayoshi Ajioka and Kazutaka Aonuma and Toshihisa Anzai and Takaharu Hayashi and Shinya Hiramitsu and Hiroya Kawai and Hidetaka Kioka and Kazuo Kimura and Lim, {Young Jae} and Ken Matsuoka and Hirohiko Motoki and Yoji Nagata and Sunao Nakamura and Nobuyuki Ohte and Yukio Ozaki and Taishi Sasaoka and Shunsuke Tamaki and Toshimitsu Hamasaki and Masafumi Kitakaze",
year = "2018",
month = "8",
day = "1",
doi = "10.1007/s10557-018-6799-5",
language = "English",
volume = "32",
pages = "381--388",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction

T2 - J-TASTE Trial

AU - on behalf of J-TASTE investigators

AU - Takahama, Hiroyuki

AU - Asakura, Masanori

AU - Abe, Yukio

AU - Ajioka, Masayoshi

AU - Aonuma, Kazutaka

AU - Anzai, Toshihisa

AU - Hayashi, Takaharu

AU - Hiramitsu, Shinya

AU - Kawai, Hiroya

AU - Kioka, Hidetaka

AU - Kimura, Kazuo

AU - Lim, Young Jae

AU - Matsuoka, Ken

AU - Motoki, Hirohiko

AU - Nagata, Yoji

AU - Nakamura, Sunao

AU - Ohte, Nobuyuki

AU - Ozaki, Yukio

AU - Sasaoka, Taishi

AU - Tamaki, Shunsuke

AU - Hamasaki, Toshimitsu

AU - Kitakaze, Masafumi

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Background: Previous studies suggest that the pathophysiology of heart failure with preserved ejection fraction (HFpEF) is characterized not only by high ventricular stiffness, but also by vascular stiffness. Azilsartan has higher vascular affinity compared with other angiotensin II receptor blockers (ARBs), which were proven to have no beneficial effects on clinical outcomes in patients with HFpEF in earlier clinical trials. We aimed to test the hypothesis that azilsartan may improve left ventricular diastolic function in HFpEF patients with hypertension in this trial. Methods: The Effects of Angiotensin Receptor Blockers on Diastolic Function in Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE trial is a multicenter, randomized, open-labeled, and assessor(s)-blinded, active controlled using candesartan, parallel-group clinical trial, to compare changes in left ventricular (LV) diastolic dysfunction between HFpEF patients with hypertension who have received candesartan or azilsartan for 48 weeks. The primary endpoint is the change in early diastolic wave height/early diastolic mitral annulus velocity (E/e’) assessed by echocardiography from the baseline to the end of the study (48 weeks). A total of 190 patients will be recruited into the study. Conclusions: The design of the J-TASTE trial will provide data on whether differences between the effects of the two tested drugs on LV diastolic function exist in HFpEF patients with hypertension and will improve understanding of the pathophysiological role of vascular stiffness on diastolic function.

AB - Background: Previous studies suggest that the pathophysiology of heart failure with preserved ejection fraction (HFpEF) is characterized not only by high ventricular stiffness, but also by vascular stiffness. Azilsartan has higher vascular affinity compared with other angiotensin II receptor blockers (ARBs), which were proven to have no beneficial effects on clinical outcomes in patients with HFpEF in earlier clinical trials. We aimed to test the hypothesis that azilsartan may improve left ventricular diastolic function in HFpEF patients with hypertension in this trial. Methods: The Effects of Angiotensin Receptor Blockers on Diastolic Function in Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE trial is a multicenter, randomized, open-labeled, and assessor(s)-blinded, active controlled using candesartan, parallel-group clinical trial, to compare changes in left ventricular (LV) diastolic dysfunction between HFpEF patients with hypertension who have received candesartan or azilsartan for 48 weeks. The primary endpoint is the change in early diastolic wave height/early diastolic mitral annulus velocity (E/e’) assessed by echocardiography from the baseline to the end of the study (48 weeks). A total of 190 patients will be recruited into the study. Conclusions: The design of the J-TASTE trial will provide data on whether differences between the effects of the two tested drugs on LV diastolic function exist in HFpEF patients with hypertension and will improve understanding of the pathophysiological role of vascular stiffness on diastolic function.

UR - http://www.scopus.com/inward/record.url?scp=85049582931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049582931&partnerID=8YFLogxK

U2 - 10.1007/s10557-018-6799-5

DO - 10.1007/s10557-018-6799-5

M3 - Article

C2 - 29974299

AN - SCOPUS:85049582931

VL - 32

SP - 381

EP - 388

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 4

ER -